INTERNATIONAL JOURNAL IN PHARMACEUTICAL SCIENCES

Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

A Comprehensive Review Of Drug-Device Combination

Yashashri K. Deore*, Sakshi V. Dashpute, Vaibhav B. Gunjal, Sejal R. Pagar, Shivraj P. Jadhav, Dhananjay M. Patil

Shreeshakti Shaikshanik Sanstha's Divine College of Pharmacy, Satana, Nashik, Maharashtra

ARTICLE INFO

Received: 26 Oct 2023
Accepted: 28 Oct 2023
Published: 02 Nov 2023

Keywords:
Drug-device combination, combination product, Drug, Device, Biological products, FDA

DOI:
10.5281/zenodo.10065508

ABSTRACT

The trend of combining drugs and devices has brought about advancements in medical product development, regulatory approval, and business involvement. These combination products are designed with modern links between key technologies and complementary elements, while still maintaining their fundamental purpose. To better understand the benefits and drawbacks of these combination medications, we will look at case studies of drug-device stents and transdermal patches. It seems that this generation of combination products has created a new, high-value area, as evidenced by advancements in product control and the realization that the competitive advantage lies in the sophistication of the mix. Recent studies show that combining technology, medicine, and biologics creates a developing opportunity. According to our analysis, a new type of combination product's first product includes both the regulator and the sponsor. If this first product is granted a license, it can greatly reduce uncertainty around the entire class of combination medications, establishing a leading regulatory center. The sponsor of a new type of combination product is crucial in reducing uncertainty by helping decision-makers understand the fundamental objective of the combination product.

INTRODUCTION

Definition and Classification of Drug-Device Combination:

A combination product is defined as any combination of two or more entities like Drug, Device, and biological products. In simpler terms, it is a single product comprising various components that serve different purposes. The components of combination products can be physically and chemically combined. [1]

There Are Two Primary Types of Combination Products:

Integral combination products: In this type, the products are made up of medical devices and medicinal products which are physically combined into a single integrated product. They worked together as one cohesive unit.

***Corresponding Author:** Yashashri K. Deore
Address: *Nandkumar Shinde College Of Pharmacy, Aghur, Vaijapur, 423701 Dist - Aurangabad, Maharashtra*
Email : yashashrideore2808@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Co-packaged combination products: In this type, the products are made up of medical devices and medicinal products which remain as separate products but are packaged together in the same secondary packaging. They are presented together but not physically integrated into a single entity. [2] A compliance evaluation may be necessary for the device component of the combination in the following ways:

Types of combination	Illustration	Device conformity evaluation
Integral combination products:	A medical device and product are combined to create a single item. Examples include: Pre-filled syringes and pens Patches for transdermal drug delivery pre-filled inhalers	If a device is not CE-marked but would need to be certified if sold separately, the applicant for marketing authorization must provide an opinion from a notified authority on the device's compliance. Article 117 of the Medical Devices Regulations' requirement will take effect on May 26, 2021. • Class I (non-sterile, non-measuring) devices are not subject to the requirement.
Co-packaged combination products	The medical product and the device are independent goods that can be found in the same box or purchased separately. Examples include: Reusable pen for insulin cartridges Tablet delivery system with controller for pain management	As required by EU medical device regulations, must have the CE mark.

Table 1: Type of DDC [3]

Methodology:

For the drug-device stent approvals, information was gathered from various sources. Firstly, data was extracted from research papers. The research also revisited the company's website and financial reports to gather additional information searched clinicaltrials.gov, recap.com, and the company's official website to gather comprehensive information about individual sponsors, clinical data, scientific publications, deals, and information related to the sponsor company and the combination products under investigation. To ensure the research adhered to the proper guidelines the PRISMA checklist and PRISMA diagram were used and are intended for better understanding of the current work.[4]

Importance of Combination Products:

Medication Improves Device Performance:

Two distinct stent generations have entered the market in the previous twenty years. The second generation used more advanced technology to provide better outcomes, but these obstacles in production and regulatory approval increased. Businesses that successfully integrated both generations gained the knowledge necessary to produce more advanced medical devices with integrated medication delivery systems. The first stent, a bare-metal stent, was authorized by the FDA in 1994. It is a metal gadget that may be expanded.

Devices Enhance Drug Delivery:

The FDA has authorized more than 70 restricted medication delivery combination products since the 1970s. Ten restricted drug delivery methods had been authorized by the 1980s, falling into three different categories: intrauterine devices, ocular implants, and transdermal patches. Wafers, buccal systems, vaginal rings, and subcutaneous implants were just a few of the controlled drug delivery solutions that underwent significant diversification in the 1990s as drug delivery technology advanced.

Innovation dynamics for combination goods: Combination product development involves a complex network of contacts between companies and regulatory bodies. Research on drug-eluting stents and transdermal patches highlights the importance of pioneers, incumbents, and regulatory agencies in product development and the primary mode of action in understanding innovation dynamics.[5]

Advantages:

Increased treatment efficacy: Using medications and technologies in combination can result in better treatment results. By boosting medication concentration at the intended area and improving therapeutic efficacy, the device component can aid in more efficient drug delivery to the target region.

Targeted drug delivery: It is made possible by drug-device combinations, allowing for the direct administration of treatments to the region that is harmed while limiting systemic exposure. As a result, the medication may have fewer adverse effects and be more generally safe.

Greater patient compliance: Combinations of drugs and devices can streamline treatment plans, making it more straightforward for patients to follow through with their recommended medicines. Better compliance and improved treatment results may result from this.

Customized pharmaceuticals: Medical professionals may create therapies that are specific to each patient's requirements by combining medications and technology. The adaptability of drug-device combinations enables personalized dosage and delivery based on elements like patient characteristics and illness progression.

Drug development that is expedited: The process of creating new medications may be time-consuming and expensive. The regulatory clearance procedure can be sped up and development times shortened by combining medications with already available or approved medical devices.

Decreased medication dose: Using a drug-device combination in some circumstances may enable a decrease in drug dosage while retaining the same therapeutic benefit. High medication concentrations, can reduce any potential adverse effects.

Synergistic outcomes: Some medication and device combinations may have synergistic effects, which are medical conditions in which the combined therapeutic advantages outweigh the total impact of each effect. The treatment of difficult medical issues can benefit greatly from this.

Better patient monitoring: Some drug-device combos have monitoring elements that let medical professionals keep track of patients' progress and change their treatments as necessary. This real-time information can be used to enhance therapy and boost patient outcomes.

Heightened market differentiation: Products that combine drugs and devices may provide consumers an edge. Companies can develop distinctive and cutting-edge treatment solutions that differentiate themselves from conventional pharmaceuticals or medical devices by integrating two or more therapeutic methods.

Expanded therapeutic options: Drug-device combos may make it possible to treat disorders that were previously challenging to treat with single-component therapy. Patients with unmet medical requirements may benefit from this particular.[6]

Disadvantages:[6]

Regulatory challenges: Compared to standard medications or medical devices alone, developing and obtaining regulatory approval for drug-device combination therapies can be more difficult and time-consuming. These items frequently need collaboration between several regulatory bodies with various standards for evaluating safety and effectiveness.

Manufacturing difficulties: Because two distinct components must be integrated into a single

product, producing drug-device combos can be technically difficult. This may result in higher manufacturing costs and possible supply chain problems.

Risk of harmful device-related incidents: In addition to the negative effects linked to the medication component, combining pharmaceuticals and devices increases the risk of device-related adverse events. Safety evaluations and post-market surveillance may become more difficult as a result.

Considering costs: Due to the additional expenses associated with research, manufacturing, and regulatory requirements, drug-device combination products are frequently more expensive than generic medications or standard medical equipment. Concerns concerning the cost and availability of these therapies may arise as a result.

Issues with intellectual property: Navigating difficult intellectual property hurdles is sometimes necessary for creating a successful drug-device combo solution, especially when using patented medications or technologies.

Restricted dosing flexibility: Given that the dosing is inextricably linked to the design of the device component, some medication-device combinations may only provide a limited amount of flexibility in changing drug doses.

Market rivalries: The level of competition in this market is probably going to rise as drug-device combos gain popularity. Challenges with market penetration and distinctiveness may result from this.

Post-market difficulties: Drug-device combination goods may require more complex monitoring and evaluation than single-drug or single-device products do for long-term safety and efficacy. To spot any new problems, post-market oversight becomes essential.

Incompatibility problems: The product's effectiveness and safety depend on the compatibility of its components, including medication stability, drug-device interactions, and storage conditions.[7]

User education and complexity: To appropriately utilize drug-device combination products, healthcare professionals and patients may need additional training. Due to their intricacy, these devices run the risk of being misused, which might affect patient results.[8]

Design And Engineering of Drug-Device Combination:

In the 1970s, combination products emerged that combined medical devices, medicines, and biological products. These products had specific effectiveness, such as antibiotic-loaded bone cement, drug-coated scaffolds, and drug-elution stents. The market for combination products rapidly expanded, including bone cement with antibiotics, stents releasing drugs, prefilled syringes, nicotine patches, and balloon catheters filled with radioactive liquid suspensions. These products were designed to reduce postoperative infection rates in artificial hip replacements and prevent blood vessel neointima hyperplasia.

Combination goods are governed by the Food and Drug Administration (FDA) in the U.S. since 1970. In 1990, the U.S. Food, Drug, and Cosmetic Act was updated to address regulatory difficulties with these goods. The definition of these goods was "constituting a combination of a drug, device, or biological product". The variety and complexity of combination goods are expanding with the advancement of manufacturing technologies. Combination goods were first described in the Code of Federal Regulations in 1991. Products that are packed together or separately yet need to be used in conjunction with one another are examples of combination products, as are physical or chemical combinations. An estimated 30% of medicinal products are combinations, according to one study. Using combination goods may come with additional hazards, even though their composition has been approved independently.

The addition of pharmaceuticals or biological components can introduce new applications and technical characteristics, potentially posing safety and effectiveness challenges. To assure the safety and effectiveness of combination goods, effective regulation is necessary given their development and complexity. Understanding and examining the definition and classification of combination goods is the first step in the optimal regulation of combination products.[9]

Mechanism And Synergy:

Explanation of how Drug-Device combination achieves enhanced therapeutic effects.

Combination medications, such as coronary stents and antibiotic-loaded bone cement, require careful consideration and justification. These drugs are often used to reduce restenosis risk in neointima hyperplasia. The product design should clearly explain the chosen medication for drug-eluting stents. Other examples include antibiotic-loaded bone cement for hip and knee prosthetic joint infections and hyaluronic acid gel with lidocaine for pain management. [10]

Key consideration for optimizing the Drug-Device interactions:

When dealing with combination products, it's essential to determine which component, whether it's medicine or the device, contributes most to the product's therapeutic efficacy through its principal mode of action (PMOA). In medical device-led products, the PMOA is based on the medical device, with pharmaceuticals supporting the goods. Research on medication work intended uses, and effectiveness duration is crucial to ensure the product is safe and effective for its intended purpose.[11]

Examples of synergistic mechanism and their significance.

On experimental plates, replicate combination blocks were used to create dose matrices. The study's research on inhibitions is limited due to the majority of chemical substances that hinder the measured endpoint, potentially due to temperature or humidity fluctuations during incubation.

The study used standard error estimates Z for median inhibition to determine synergy between drugs. The method involved comparing the combined response to individual drugs to assess if a combination is more effective than the medication-with-itself "Loewe additivity" level. This threshold is crucial in determining the advantage of combining drugs beyond simply raising component drug doses, making it a crucial factor in therapeutic combination. An empirical conversion from MAD (Median Absolute Deviation) to standard deviations was used.[12]

Supplementary Materials:[12]

Suppl. Note 1: Selectivity and synergy simulations.

Suppl. Note 2: Simulations of bacterial metabolism using flux balance.

Suppl. Note 3: Statistics and outcomes of an experimental screening.

Suppl. Note 4: Specifics and follow-up for specific synergy cases.

Suppl. Data 1: Statistical findings from the simulated screens.

Suppl. Data 2: Annotations of genes and pathways for the FBA simulations.

Suppl. Data 3: FBA simulations with a single inhibitor activity.

Suppl. Data 4: Data on synergy and selectivity for FBA simulations.

Suppl. Data 5: Chemicals that were employed in the experimental screens.

Suppl. Data 6: Data on selectivity and synergy for the experimental screens.

Suppl. Data 7: Results of the experimental screens in terms of statistics.

Suppl. Data 8: Follow-up information regarding the hypothetical selective synergies.

Suppl. Data 9: Data for the glucocorticoid-TCA synergy in vivo.

Emerging Technologies and Innovations:

Computation models and simulations:

Computational modeling and simulation (CM&S) are utilized in medical device development to assess their effectiveness. The FDA's "Credibility of Computational Models Program" reduces the risk of incorrect judgments. The Office of Science and Engineering Laboratories conducts research on CM&S related to medical devices. CM&S can simulate clinical environments for virtual patients, reducing clinical trials and assessing risks, improving patient safety, and reducing the cost and time required for clinical research.

CM&S is a method that can effectively study coronary artery drug deposition in overlapping drug-eluting stents, addressing challenges related to complex three-dimensional geometry and drug delivery. It can simulate flow-mediated drug transport of combination products, analyzing their mechanics and release characteristics, and providing recommendations and scientific evidence for their use in clinical applications. [13]

Novel approaches:

To promote the development of novel medical items, several nations have put laws and regulations in place. These countries keep a careful eye on this field because of its relevance. The "Breakthrough Therapy/Device Recognition" program of the FDA is intended to hasten the development and assessment of novel treatments for serious or life-threatening diseases. The Food and Drug Administration Safety and Innovation Act (FDASIA), which was enacted into law on July 9, 2012, allowed for this categorization. The FDA's new categorization, which incorporates fast track, rapid approval, and priority review, is a distinctive review procedure. Products used in regenerative medicine are governed by regulations in Japan under the updated Pharmaceutical Affairs Law. A Regulatory Science Centre was established by the Pharmaceutical and Medical Device Agency (PMDA) in Japan in 2018 to improve the evaluation and safety of regenerative healthcare products.[13]

Innovative technologies:

Due to ongoing technological breakthroughs that seek to address unmet clinical requirements, medical goods that mix several components, such as those used in cardiovascular, orthopedic, and neurological uses, have developed into a separate category of medical products. Stents that release medications, catheters with antimicrobial coatings, bone cement injected with antibiotics, and wound stickers with antimicrobial and anti-inflammatory qualities are a few examples of such items which are some of the currently marketed and known combination products. Additionally, new hybrid goods are being created, including chip-enabled smart pills, tissue-engineering medical devices, and bioartificial liver devices. The therapeutic benefits of each of these combo products are based on cutting-edge, novel technology.[14]

Drug Delivery System Technologies:

These systems aim to deliver drugs more efficiently with minimal side effects. Introduction to different drug delivery methods used in the combination products, Medication administration has long been done using traditional medication delivery methods. To increase safety, efficacy, and patient compliance, pharmaceutical companies are creating innovative drug delivery systems. Numerous pharmaceuticals can now be administered using a variety of traditional dose forms, including creams, pills, injectables, and more thanks to medical application systems.

Drug delivery refers to the procedure of giving medication to people or animals to have a therapeutic effect. The importance of nasal and pulmonary administration techniques for treating human ailments is rising. In particular for peptides and protein therapeutics, these techniques provide possible substitutes for parenteral drug delivery. For respiratory and nasal administration,

numerous pharmaceutical delivery methods have been created and are currently being studied. These methods include, among others, cyclodextrins, prodrugs, microspheres, gels, and liposomes. The stringent criteria necessary for medication delivery are anticipated to be met by nanoparticles constructed of biodegradable polymers. They must be able to become an aerosol, withstand the pressures produced during aerosolization, which be biocompatible, target certain lung regions or populations of cells, release medicines in a specified way, and dissolve inside the body. [15]

Evaluation of novel technologies for enhanced drug delivery.

The utilization of distribution methods has significantly aided in the creation of potent medications. administration techniques and technology evolved to accommodate the changing demands of drug administration as the therapeutic environment altered over time. Small-molecule drugs were the main kind of therapy accessible decades ago. As a result, attempts to administer them were concentrated on improving their solubility, controlling their release, increasing their activity, and modifying their pharmacokinetics (PKs). This is because tiny molecules' bioavailability is greatly influenced by their physicochemical characteristics. However, as new generations of medicines evolved, they carried with them brand-new therapeutic qualities, including peptides and proteins, monoclonal antibody nucleic acids, and live cells.

Additional difficulties were brought on by the new activities, specifically in the areas of stability for the proteins and peptides, needs for intracellular transport, and viability and growth. To meet these obstacles, drug delivery systems have to change.[16]

Limitations:

Regulatory hurdles, manufacturing complexities, and reimbursement issues:

We only used instances from the internet that were available to everyone for our analysis. But in situations supplied by the Food and Drug Administration (FDA) as Capsule judgments, the novel visualization methods proposed in this paper may be used. The FDA was creating, looking into, or studying combinations of products; thus, we were not to examine any of them. Furthermore, we did not examine instances of combination items or goods that included medical and technological components in other nations or jurisdictions. It's important to keep in mind that the US, as opposed to the nation of Japan, the United Kingdom, and EU member states, has separate regulatory regimes for combination goods. The regulatory environment for device-medicinal product combinations is also evolving as a result of the new European Union Medical Device Regulation.

The terms PIU and PMOA may still be used interchangeably even if the legal frameworks and definitions of combination products differ across the US, EU, and Japan. The novel models suggested in this paper may be used in the EU, Japan, and other nations. The usefulness and application of these models can be enhanced by more studies on the classification of innovative combination goods in other jurisdictions.

Additionally, Regulatory agencies in some other nations have a category for borderline items that includes both combinations and single products that are challenging to classify as drugs, biologics, or devices. However, both combination therapies and single-entity borderline goods may be able to benefit from these approaches. In-depth knowledge of PIU and PMOA as well as the exchange of ideas on how regulatory authorities in various nations and jurisdictions have designated PIU and PMOA must be required and crucial if global convergence is to be facilitated.

An innovative visualization strategy for classifying combination goods is presented in this paper. This model may be used to create unique

combination goods with brand-new conceptual and mechanistic parts as well as new technologies including drug-device combinations, advanced therapeutic products (ATP) with device elements, and medical devices constructed of cutting-edge materials. However, a greater comprehension of their explanations, safety, and efficacy is required, in addition to an examination of their PIU and PMOA, to appropriately identify and regulate these medicines. [17]

Market Trends and Commercialization:

Analysis of the market landscape for Drug-device combination products in different regions: The development, approval, and commercialization of medical products have been impacted by the introduction of drug-device combination products. These products have also provided valuable insights that can guide the creation of future combination products. Boston Scientific unveiled two new devices in their peripheral drug-eluting product line at the Vascular Inter Ventional Advances (VIVA) conference in Las Vegas in November 2019, following separate late-breaking clinical trial presentations. The "Ranger Drug-Coated Balloon (DCB)," together with the "Eluvia Drug-Eluting Vascular Stent (DES)," are the devices that were discussed. In a pivotal study conducted in the United States, these products demonstrated the greatest primary patency recorded to date for the treatment of femoropopliteal illness. Additionally, this market is expanding at a faster rate due to an increase in the incidence of chronic disorders including diabetes, heart disease, cancer, and multiple sclerosis. The World Health Organization (WHO) estimates that by 2020, cases of chronic diseases will account for nearly 75% of all deaths worldwide, with developing nations accounting for 70% of deaths from diabetes, 75% of deaths from stroke, and 71% of deaths from ischemic heart disease (IHD).[18]

Global Trends:

Three major patterns have emerged as a result of the worldwide maturity of drug-device combination products:

Expansion of Medical Device Adoption for Drug Delivery:

Medical gadgets provide a practical, confidential, and secure method for giving pharmaceuticals to patients and medical professionals. Combination product applications have steadily increased, with 518 submissions in 2019 showing an annual rise of 10% over the previous five years, according to the US Food and Drug Administration (US FDA). This expansion shows how popular medical gadgets for delivering drugs are becoming. The market for combination goods is anticipated to rise to $139 billion by 2025, with a compound annual growth rate of 7%.

Drug Delivery System Complexity is Growing:

New treatments and delivery systems have led to increased complexity in technical development, product quality, regulatory compliance, and supply chain management.

Developing Technology:

For instance, a comprehensive examination of the components, interactions, and overall operation of a customized pump that combines mechanical and electrical parts and incorporates software to dispense thick biological fluids is necessary. To make the combination product successful, the medication and the device must be combined in complex ways.

Product Excellence:

Establishing quality procedures for both the component elements and the combined product is crucial to guarantee that the medication and device work consistently throughout the clinical and commercial stages. This entails establishing quality procedures for the biological ingredient as well as designing and buying control for an autoinjector that delivers biologics. According to 21 CFR 820, other elements like CAPA and management responsibilities must additionally

have a quality system in place. The performance of the product may be preserved during its life by putting these mechanisms in place.

Regulatory:

The criteria for determining the most effective regulatory procedure for complex product configurations include the major mode of action, regulatory precedents, and market experience with similar products.

A worldwide logistics and supply chain system is necessary to manage a variety of product variations. The supply network for combination products comprises manufacturing the drug material, excipients, pharmaceutical products, and device parts, assembling the constituent parts, packing, and labeling at various sites across the world. Variations in product arrangements, regulatory status, and national labeling must all be taken into account throughout transportation, storage, distribution, and labeling.

Increasing Concern about Product Experience and Risk:

Health authorities all around the globe have put transparency regulations into place that provide easier access to sales performance information for healthcare items. The Adverse Event Reporting System (FAERS) of the US Food and Drug Administration is a web-based tool that offers comprehensive data on adverse events in a dashboard style. Similar to this, platforms like Open Vigil have increased the accessibility of global pharmacovigilance data. Due to the expanding public engagement in these platforms, healthcare products and hazards are widely addressed on international social media platforms, such as social networking pages, microblogs, Wikipedia, and media-sharing websites. [19]

Opportunities And Development:

Adding to the utilization of clinical development devices:

It is anticipated that by the time pivotal clinical trials begin, the device will have reached the most advanced stage of development (i.e., will meet the pertinent GSPRs), given the device's contribution to the secure and efficient delivery of a medicinal substance.

Although it is not within the purview of this guideline and is a national matter, the MAA provides the following guidance:

Integral DDC:

For devices included in integral DDCs utilized in clinical development, no proof of compliance with the applicable GSPR needs to be submitted. From the beginning of the pivotal clinical trials to the product that is proposed for marketing in the MAA, the effects of any changes in devices should be described, assessed, and justified in terms of any potential impact on the quality, safety, and efficacy of the medicinal product. In cases when the device is altered, Modules 3 and 5 may call for data to "bridge" the various device designs from the standpoints of safety and efficacy. In Module 3.2.P.2.4, a risk assessment that details the modifications, batches utilized, trial(s), and mitigation steps taken to lessen the influence on product quality, should be provided.

Non-integral DDC:

In cases where the device and clinical investigations were incorporated into the pivotal DDC clinical trial due to their relevance to the MAA and the fact that they could not be separated from the investigation of the medicinal product, the justification for this strategy should be covered and justified in Module 5. C [20]

Challenges Faced in Drug-Device Combination:

Addressing the current challenges faced in research, development, and commercializing the Drug-Device combination.

Different Pathways for Regulatory Approval

Combination products raise unique regulatory concerns, making assignments difficult. The determination of the product's PMOA is the basis for the assignment. The FDA's Centre for Drug

and Evaluation Research (CDER) has primary jurisdiction over the combination product if PMOA was caused by the drug product.

Similarly, the center in charge of the device's premarket evaluation would have primary jurisdiction over the device-drug combination product if the PMOA of the latter was due to the former. In this situation, the Centre for Devices and Radiological Health (CDRH) is the lead center. In charge of examining the application, the relevant center will also confer with the other center regarding the pertinent component of the drug-device combination. The difficulty is that every center does things differently. Drugs and gadgets have slightly differing evidential requirements. As a result, each center has its ideology towards the regulation of the component falling within its purview, as well as its conception of the type of information that is secure and reliable enough to justify approval. This can occasionally result in misalignment among the review team, which might cause hiccups for the Sponsor.

Expertise.

The sponsors of drug-device combo products often have extensive knowledge in one of the two subfields. They have a lot of expertise with either the medicine component or the gadget component. The FDA expects them to present strong data in both categories, regardless of the approval method, which can be difficult. To submit their application, the Sponsor must thus figure out how to acquire the required knowledge.

Cost and Time.

Each component of a combination product must pass both individual and joint testing, according to FDA regulations. To get the Agency's clearance for a combination product, a lot more documentation must be provided. As a result, compared to developing a single entity, the total cost and duration may be significantly higher.

Risk of Interaction:

The FDA anticipates that Sponsors would consider all potential hazards brought on by component interactions. Because all of the parts are in direct touch with one another, either physically or programmatically, there might be interactions that endanger the user. This necessitates doing testing that is expressly aimed at reducing such hazards.

Human Factor.

For drug-device combinations, the FDA frequently demands a human factors study, especially when the product is intended for use by the patient or carer. When cross-labeling the device and medication constituent parts, it's essential that each component has sufficient warnings and directions for usage, and that they are uniform across the board. The regulatory procedure becomes more time-consuming, costly, and complex as a result of these requirements.[21]

Comparison of regulatory pathways with traditional drugs and medical devices:

Many of the same challenges that face the development and administration of individual medicines also face the development and delivery of combination pharmaceuticals, but the inherent complexity of such products raises the risk of adverse effects. The following are some typical challenges:

It might be difficult to feel fully informed on the most recent rules and guidelines because regulatory systems throughout the world are complex and changing, especially when it comes to combination products. A customer's research by West discovered that the most common challenge faced by pharmaceutical companies when creating combination medicines is the complicated regulatory environment. The interaction of a device and a drug is essential for combination goods. To completely and accurately understand how one component impacts the other, drug and device producers must work together closely from the start of the development process. This will

guarantee that the appropriate tools and administrative procedures are employed.

Drug volume is still another significant device concern since greater dosages (by size or volume) might cause more problems. Patient self-administration of systems with bigger volumes and higher viscosities is a relatively new concept, and it has driven the need for systems that can adapt appropriately. It might be difficult, though, to keep up with the shifting expectations. When developing drug-device combination products, it is important to consider how the medicine or device may affect the product.

Optimised and reliable Product Integrity and Quality are influenced by a wide variety of factors that might be difficult to control or avoid. The interaction between medication delivery mechanisms and containers is significantly more complex in combination products. If the quality of a drug is damaged, all the efforts made to get it into the hands of a patient are, at best, for naught, and, at worst, patients may be put in danger.

Device manufacturers require a categorized principal mode of action that is to be used properly to establish the regulatory and product improvement framework.[22]

Solutions And Recommendations on Challenges Faced in Drug-Device Combination:

Companies that sell combination items and are in the pharmaceutical and device industries typically run into the aforementioned issues. Real solutions are fortunately feasible thanks to efficient testing and control, simplified development procedures, and synergistic success-oriented behaviors.

It's crucial to promote creativity in a continually changing environment by carefully evaluating the result. This includes having systems in place to keep them in mind throughout the development process and beginning with a clear understanding of user and patient expectations as well as the profile of the medication target product.

To do this, risk management planning and preparation are necessary, as is the establishment of procedures and policies to identify risks, foresee and analyse potential obstacles, reduce and manage risk, and track and evaluate results.

To solve problems with patient-administered combination drugs with higher drug volumes, recent innovation is starting to alter the potential of wearable devices that deliver medication subcutaneously. Manufacturing and packaging challenges for combination products will change as pharmaceutical types and dosages change, but techniques that support patient-centered care continue to evolve.

From a regulatory perspective, it is essential to comprehend and keep up with relevant governance, which encompasses a variety of devices and containers. The device manufacturer or supplier is a source of guidance and feedback that drug companies may and regularly do, particularly when submitting. We keep expanding our knowledge and skills so that we can help customers not only understand the international rules that have an impact on the creation of combination products but also design and carry out the studies necessary to demonstrate the compliance that is required from the development stage through to and after commercialization.

To create, conduct, and interpret suitable study designs that encompass syringes, cartridges, vials, and other related components and equipment, device and package makers must work with customers to enhance their understanding of current laws and regulations. When drugs and devices are produced individually for individual items, the processes used are very different from those used when they are produced collaboratively and in unison for combination products.

To constantly create and supply the best quality medication and devices, rigorous testing that attempts to discover and decrease risks, adhere to standards, and concentrate on continuity is

required. In the end, this will make it possible to provide medication to patients in a long-term, secure, and efficient manner.

To ensure that a product's quality and integrity are preserved from conception to delivery, rigorous and complex testing is required, ranging from extractible and particle analysis to product purity and stability. When possible, testing to measure these factors should be carried out by industry standards; alternatively, when specific standards are still lacking for a particular combination, testing should be based on related standards and take into account all of the critical elements of the drug preparation and delivery process.

Design verification studies for combination products prioritize risk minimization, adherence to standards, and examining device component performance. These studies assess physiochemical interactions, ensuring high-quality products are approved and marketed quickly. Verification testing ensures device construction, function, and performance against external factors and patient needs. It also assesses product durability in harsh conditions like drops, temperature fluctuations, and moisture exposure. Additionally, it is crucial to analyse end users' locations and methods.

Combination goods regulation is the legal framework and monitoring that ensures safety, efficacy, and quality for patients. Governments demand pre-market approval, labeling requirements, and post-market monitoring for safety issues. Combining technical and medical competence, regulation is complex and diverse, with organizations like the European Medicines Agency and the USFDA significantly impacting the process.[23]

Case Studies in Drug-Device Combination:

Case study's methodology and sectoral relevance:

In this case study, the value proposition formulation, market analysis, product/service definition, and use-case analysis were all done using Morelli's seven-step approach. Particularly for the business-to-business PSS, individual interactions with contract partners (in this example, pharmaceutical businesses) are substituted for the testing phase and final specification. The PSS must be uniquely designed for a particular client rather than having the market challenge the system. Only the general portion of the development is described in this case study. A pharmaceutical firm and a medical device company collaborated to conduct a global clinical trial, and significant components of the business-to-business model described in the case study were used in this process. Then, based on a review of the partnership, this basic model was changed. The improved model has been shown accurate about business-relevant factors in multiple expert conversations between medical device company B and pharmaceutical firms similar to pharmaceutical company A. The business-to-customer model was created using expert conversations between pharmaceutical company A and medical device company B, and it was then confirmed using expert discussions between medical device company B and pharmaceutical firms that are very similar to pharmaceutical company A. The treatment of aggressive brain tumors or neurodegenerative illnesses via direct, CED injections of therapeutic substances into brain tissue is discussed in the case study that follows. The transition from research to commercialization of this ground-breaking therapeutic procedure necessitates a highly multidisciplinary approach. The case study's findings should be broadly relevant to the more general, developing market of drug-device combos because the therapy involves both medications and several medical devices. A new development in the medical industry is the use of medications in conjunction with medical devices. This is especially true for local delivery, which requires collaboration between pharmaceutical firms and

medical device makers on research and development difficulties. Local drug delivery provides for the precise placement of the medicine at the site in the body where it is required, as opposed to systemic drug administration, which involves giving pharmaceuticals via tablets or intravenous injection. This results in a high therapeutic concentration at the target and a relatively low systemic concentration throughout the body, resulting in fewer side effects and reduced toxicity. To combat this tendency, regulatory organizations like the FDA have established rules. In light of this, the European Commission has also released rules for integrated devices.[24]

Technological background:

Despite significant medical advancements, one of the most pressing unmet medical needs continues to be the treatment of brain-related illnesses such as certain severe brain tumors and several neurodegenerative disorders. The "blood-brain barrier" (BBB), which guards against the brain being harmed or poisoned by chemicals in the bloodstream, is largely to blame for this. This barrier, while essential for healthy individuals, presents a significant challenge for the treatment of several CNS illnesses. Over the past few decades, promising drugs that had great promise in pre-clinical studies for the treatment of primary brain tumors like glioblastoma multiforme or neurodegenerative diseases like Parkinson's, Alzheimer's, multiple sclerosis, and epilepsy have failed in human trials. Those poor findings were most likely caused by the medication molecules failing to reach their intended location in the brain. CED is a possible strategy to get around the BBB. By inserting a catheter into the clinical target and using a positive pressure gradient to force the medication into the tissue, the medicine is directly administered to the target region within the brain tissue. This method, which appears straightforward on the surface, has proven to be quite difficult in practice since it strongly depends on the anatomical structures and pathologies unique to the patient for medication distribution. Therefore, planning is a very important component of the treatment, and the method necessitates a multidisciplinary approach to make a meaningful improvement in the patient outcome.[24]

CONCLUSION

In this study, we identified drug-device combination products as a fresh pattern of medical product development, regulatory acceptability, and market participation. Combination goods are architectural innovations because they uphold a fundamental idea while reinforcing it via intricate connections between updated complimentary components and core technologies. To better understand the drawbacks and advantages that combination medications have over earlier iterations of traditional medicinal or drug delivery systems, this study examines case studies of drug-device stents and transdermal patches. The advancements in combination product control and the discovery that the complexity of the combination is what gives current combination goods their competitive edge tend to point to the production of combination products as having established a new high-value market. This is a developing opportunity, according to current studies into novel inventions that combine technology, medicine, and biologics. The regulator and the sponsor are presented in the first product of a new type of combination products, according to our analysis. The degree of uncertainty around the entire class of combination medications is greatly reduced if the first product is granted a license, which may result in the establishment of the leading regulatory center. The sponsor of a new type of combination product is crucial in reducing this uncertainty by guiding the decision-maker on the combination product's principal objective. Combination drug-device solutions, in general, are a ground-breaking technical category

in contemporary drug delivery systems, combining a unique set of performance, architecture, implementation, and, in certain circumstances, corporate collaboration and technology licensing. This new class of therapeutic products has had an impact on the development of medical products, regulatory approval processes, and organizational involvement.

REFERENCES

1. Latoz, C., Larkin, L., & Huynh-Ba, K. (2023). Stability considerations for drug-device combination products-21 CFR part 4 update. AAPS Open, 9(1), 1-14.
2. Choi, S. H., Wang, Y., Conti, D. S., Raney, S. G., Delvadia, R., Leboeuf, A. A., & Witzmann, K. (2018). Generic drug-device combination products: Regulatory and scientific considerations. International Journal of Pharmaceutics, 544(2), 443-454.
3. Cooke, E. (2022). Preparing Europe for future health threats and crises─ the European Medicines Agency; ensures safe and effective medicines and medical devices. Eurosurveillance, 27(42), 2200798.
4. Pourkavoos, N. (2012). Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. Combination Products in Therapy, 2, 1-31.
5. Couto, D. S., Perez-Breva, L., Saraiva, P., & Cooney, C. L. (2012). Lessons from innovation in drug-device combination products. Advanced drug delivery reviews, 64(1), 69-77.
6. Chandrasekaran, G., & Rajalakshmi, A. N. (2019). Fixed dose combination products as Oro-dispersible tablets: A review. Journal of Drug Delivery and Therapeutics, 9(2), 563-573.
7. Netland, P. A., & Tanna, A. P. (Eds.). (2020). Glaucoma medical therapy: principles and management. Kugler Publications.
8. Mitra, A., & Wu, Y. (2012). Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. The AAPS journal, 14, 646-655.
9. Mitra, A., & Wu, Y. (2012). Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. The AAPS journal, 14, 646-655.
10. Tian, J., Song, X., Wang, Y., Cheng, M., Lu, S., Xu, W., ... & Zhang, X. (2022). Regulatory perspectives of combination products. Bioactive Materials, 10, 492-503.
11. Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., ... & Borisy, A. A. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology, 27(7), 659-666.
12. Tian, J., Song, X., Wang, Y., Cheng, M., Lu, S., Xu, W., ... & Zhang, X. (2022). Regulatory perspectives of combination products. Bioactive Materials, 10, 492-503.
13. Tian, J., Song, X., Wang, Y., Cheng, M., Lu, S., Xu, W., ... & Zhang, X. (2022). Regulatory perspectives of combination products. Bioactive Materials, 10, 492-503.
14. Verma, R. K., & Garg, S. (2001). Drug delivery technologies and future directions. Pharm. Technol, 25(2), 1-14.
15. Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., & Bannerjee, S. K. (2012). Drug delivery systems: An updated review. International journal of pharmaceutical investigation, 2(1), 2.
16. Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021). The evolution of commercial drug delivery technologies. Nature Biomedical Engineering, 5(9), 951-967.
17. Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021). The evolution of commercial drug delivery technologies.

Nature Biomedical Engineering, 5(9), 951-967.

18. Uemura, N., Kasanuki, H., & Umezu, M. (2021). New Visualization Models of Designation Pathway and Group Categorization of Device–Drug and Device–Biologic Combination Products Classification in the United States: Analysis of FDA Capsular Decisions. Therapeutic Innovation & Regulatory Science, 55, 807-817.
19. Kumoluyi, R., & Khanolkar, A. (2022). Risk Management in Drug-Device Combination Product Development. Therapeutic Innovation & Regulatory Science, 56(5), 685-688.
20. Panchal, K., Katke, S., Dash, S. K., Gaur, A., Shinde, A., Saha, N., ... & Chaurasiya, A. (2023). An expanding horizon of complex injectable products: Development and regulatory considerations. Drug Delivery and Translational Research, 13(2), 433-472
21. https://www.propharmagroup.com/thought-leadership/the-unique-challenges-of-gaining-approval-for-drug-device-combos
22. https://corpbiz.io/learning/challenges-faced-in-drug-device-combination-products/#Challenges_Faced_In_Drug_Device_Combination_Products
23. https://a3p.org/wp-content/uploads/2020/04/produits-combines-injectables-2-vague-65-a3p.png
24. https://corpbiz.io/learning/challenges-faced-in-drug-device-combination-products/#Challenges_Faced_In_Drug_Device_Combination_Products.

HOW TO CITE: Yashashri K. Deore*, Sakshi V. Dashpute, Vaibhav B. Gunjal, Sejal R. Pagar, Shivraj P. Jadhav, Dhananjay M. Patil, A Comprehensive Review Of Drug-Device Combination, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 11, 56-70. https://doi.org/10.5281/zenodo.10065508